Core Viewpoint - The company has been deeply engaged in the in vitro diagnostics industry for many years and possesses a rich portfolio of in vitro diagnostic reagents and instruments [1] Group 1 - The company will closely monitor industry development trends and market demands [1] - The company plans to formulate business strategies based on actual business needs and development strategies [1] - The company aims to actively seize business opportunities [1]

Group 1 - The core viewpoint of the article is that Kewah Bio acknowledges the differences in product development strategies and market focus compared to its competitors in the internet healthcare sector [1] - Kewah Bio emphasizes that each company has distinct main products, technical paths, and market needs, which influence their business strategies [1] - The company expresses its commitment to closely monitor industry trends and market demands to formulate its business plans and seize relevant opportunities [1]

Core Viewpoint - Kehua Bio has received a medical device registration certificate from the National Medical Products Administration for its Hepatitis A Virus IgM Antibody Test Kit, which is expected to positively impact the company's business development and enrich its product line [1]. Group 1 - The product is designed for the qualitative detection of Hepatitis A Virus IgM antibodies in human serum or plasma [1]. - The acquisition of the medical device registration certificate signifies a regulatory approval that enhances the company's product offerings [1]. - The introduction of this new product is anticipated to have a positive effect on the company's business growth [1].

上海科华生物工程股份有限公司 关于2025年第四季度可转债转股情况的公告 | 证券代码：002022 | 证券简称：科华生物 | | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | 公告编号：2026-001 | | 证券代码：002022 | 证券简称：科华生物 | | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | | 转股价格：人民币20.64元/股 | | | 转股期限：2021年2月3日至2026年7月27日 | | 根据《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自律监 管指引第15号——可转换公司债券》的有关规定，上海科华生物工程股份有限公 司（以下简称"公司"）现将2025年第四季度可转换公司债券（以下简称"可转 债"）转股及公司股份变动情况公告如下： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 一、可转债发行上市基本情况 1、 可转债发行情况 经中国证监会"证监许可[2020]970号文"批准，公司于2020年7月28日公开 发行了73 ...

| 证券代码：002022 | 证券简称：科华生物 | | --- | --- | | 债券代码：128124 | 公告编号：2026-002 债券简称：科华转债 | 近日，上海科华生物工程股份有限公司（以下简称"公司"）收到国家药品 监督管理局颁发的医疗器械注册证（体外诊断试剂）。具体情况如下： | 序号 | 产品名称 | 注册证编号 | 注册证有效期 | 适用范围/预期用途 | | --- | --- | --- | --- | --- | | | 甲型肝炎病毒 IgM抗体检测 | 国械注准 | 2025年12月31日 | 本产品用于体外定性检测 人血清或血浆中的甲型肝 | | 1 | | | 至 | | | | 试剂盒（化学 | 20253402761 | 2030年12月30日 | 炎病毒IgM抗体（Anti-HAV | | | 发光法） | | | IgM）。 | 以上新产品医疗器械注册证的取得，丰富了公司产品线，将对公司业务发展 具有正面影响。公司目前尚无法预测上述产品对公司未来营业收入的影响，敬请 投资者给予关注并注意投资风险。 特此公告。 上海科华生物工程股份有限公司董事会 2026年1月6日 ...

智通财经APP讯，科华生物(002022.SZ)公告，公司收到国家药品监督管理局颁发的医疗器械注册证(体 外诊断试剂)，产品名称为：甲型肝炎病毒IgM抗体检测试剂盒(化学发光法)。 ...

科华生物（002022）(002022.SZ)公告，公司收到国家药品监督管理局颁发的医疗器械注册证(体外诊断 试剂)，产品名称为：甲型肝炎病毒IgM抗体检测试剂盒(化学发光法)。 ...

科华生物公告称，近日收到国家药监局颁发的医疗器械注册证（体外诊断试剂），产品为甲型肝炎病毒 IgM抗体检测试剂盒（化学发光法），注册证编号为国械注准20253402761，有效期从2025年12月31日 至2030年12月30日，用于体外定性检测人血清或血浆中的甲型肝炎病毒IgM抗体。该注册证丰富了公司 产品线，对业务发展有正面影响，但暂无法预测对未来营收的影响。 ...

Core Viewpoint - The company is actively managing its inventory based on actual production and operational conditions, while continuously innovating marketing strategies and optimizing internal management to enhance inventory management levels [2]. Group 1 - The company is responding to investor inquiries regarding its inventory management practices [2]. - The company emphasizes the importance of adapting inventory management to real-time production and operational circumstances [2]. - The company is focused on innovation in marketing and internal management to improve overall efficiency [2].

Group 1 - Guangqi Technology's controlling shareholder proposed a share buyback of 50 million to 100 million yuan for employee stock ownership plans or equity incentives [1] - Xingyuan Zhuomai received a supplier designation from a domestic electric vehicle manufacturer to develop and supply reducer shell components, with expected sales of approximately 575 million yuan over four years from 2027 to 2030 [2] - Weigao Bio's application for clinical trials of subcutaneous human immunoglobulin has been accepted by the National Medical Products Administration, targeting primary immunodeficiency diseases [3] Group 2 - Hongda Electronics disclosed uncertainty regarding the IPO progress of its associate Jiangsu Zhanxin, in which it holds a 13.79% stake [4] - Kangchen Pharmaceutical received FDA approval to conduct clinical trials for its KC1086 project, aimed at treating advanced recurrent or metastatic solid tumors [5] - Kweichow Moutai adjusted its share buyback price ceiling to 1863.67 yuan per share, effective from December 19, 2025 [6] Group 3 - Mousse Co. announced that its controlling shareholder and actual controllers committed not to reduce their holdings within one year [7] - Tongxingbao's subsidiary signed a business contract worth 43.166 million yuan for a cloud expansion project [8] - Kaifa Electric announced plans for three shareholders to collectively reduce their holdings by 0.6999% [9] Group 4 - Longpan Technology plans to increase the production capacity of lithium iron phosphate cathode materials from 62,500 tons per year to 100,000 tons per year [10] - Zhuhai Guanyu announced plans for two shareholders to reduce their holdings by up to 3% [11] - Jiaheng Home Textiles is planning a change in control, leading to a temporary suspension of its stock [12] Group 5 - Kehua Bio's subsidiary received a medical device registration certificate for a gene polymorphism detection kit [13] - Saitex New Materials' actual controller plans to reduce holdings by up to 3% [14] - Sanhui Electric announced a shareholder's plan to reduce holdings by up to 2% [15] Group 6 - Binhua Co. plans to establish a venture capital fund with a total scale of 400 million yuan, focusing on strategic emerging industries [16] - Jindun Co. announced plans for two shareholders to reduce their holdings by up to 4% [17] - Hengdian East Magnetic's controlling shareholder plans to reduce holdings by up to 1% [18][19] Group 7 - Luxin Investment's controlling shareholder plans to reduce holdings by up to 1% [20] - Huakang Clean announced a joint bid for a hospital procurement project worth 157 million yuan [21] - Xuedilong plans to reduce its repurchased shares by up to 488,560 shares [22] Group 8 - Enhua Pharmaceutical's subsidiary signed an exclusive commercial cooperation agreement for three long-acting antipsychotic products [23] - Aier Eye Hospital plans to acquire partial equity in 39 institutions for a total of 963 million yuan [24] - Gaozheng Mining plans to acquire 100% equity of Overseas Explosives for 510 million yuan [25] Group 9 - Donghong Co. plans to repurchase shares worth 30 million to 60 million yuan for employee stock ownership plans [26] - Bear Electric's controlling shareholder plans to reduce holdings by up to 0.64% [27] - *ST Zhengping announced the initiation of pre-restructuring by the Xining Intermediate Court [28][29] Group 10 - Caesar Travel's shareholder plans to reduce holdings by up to 3% [30] - Lianchuang Electronics announced a change in controlling shareholder to Jiangxi State-owned Assets Supervision and Administration Commission [31] - Beixin Road and Bridge plans to transfer 5.33% equity in Henan Yuhang for 243 million yuan [32] Group 11 - Fenglong Co. is planning a change in control, with stock resuming trading [33]